Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain.

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict (1991) 63.91

Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79

Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol (2007) 5.48

Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab (2000) 2.95

Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab (1996) 2.66

Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab (2002) 2.58

Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry (2006) 2.53

Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31

Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol (2000) 2.29

Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab (1993) 2.28

Positron emission tomography compartmental models. J Cereb Blood Flow Metab (2001) 2.28

Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther (2012) 1.82

Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron (2012) 1.81

5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol (2000) 1.67

beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53

Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab (2011) 1.36

PET physiological measurements using constant infusion. Nucl Med Biol (2000) 1.35

In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med (2005) 1.18

123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med (2005) 1.14

Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. J Cereb Blood Flow Metab (1998) 1.13

Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol (2005) 1.13

Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition. Synapse (2007) 1.09

Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab (1992) 1.09

123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med (2007) 1.08

Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry (2012) 1.07

Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry (2014) 1.06

Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 1.05

Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. Neuroimage (2007) 1.04

Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse (2003) 1.00

Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology (2004) 1.00

Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry (2012) 0.97

PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med (2012) 0.90

Imaging changes in synaptic acetylcholine availability in living human subjects. J Nucl Med (2012) 0.90

SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug Alcohol Depend (2010) 0.89

In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport (1998) 0.89

Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem (2008) 0.88

Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys. Synapse (2005) 0.88

Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol (2006) 0.88

In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro-fluoro-homoepibatidine. Synapse (2008) 0.87

Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain. Brain Res (2000) 0.87

Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry (2013) 0.86

In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry (2013) 0.83

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab (2009) 0.83

PET imaging of acetylcholinesterase inhibitor-induced effects on α4β2 nicotinic acetylcholine receptor binding. Synapse (2013) 0.82

PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics. J Nucl Med (2013) 0.82

Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco (2004) 0.82

Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. Nucl Med Biol (1999) 0.81

First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine. Neuroimage (2015) 0.80

Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (-)-[(18)F]Flubatine in humans. Nucl Med Biol (2014) 0.80

123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med (2009) 0.80

Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology (Berl) (2015) 0.79

Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand 18F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys. Synapse (2014) 0.77

Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. Nucl Med Biol (2014) 0.76

Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment. Transl Psychiatry (2017) 0.75